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KEY POINTS: 50 
 51 
 HyperD-ALL shows a delay in early mitosis at prometaphase associated to defects in 52 
chromosome alignment and segregation. 53 
 Impaired condensin complex leads to defective AURKB, triggering chromatid cohesion 54 





B-cell acute lymphoblastic leukemia (B-ALL) is the most common pediatric cancer, and high-60 
hyperdiploidy (HyperD) identifies the most common subtype of pediatric B-ALL. Despite HyperD 61 
is an initiating oncogenic event affiliated to childhood B-ALL, the mitotic and chromosomal 62 
defects associated to HyperD B-ALL (HyperD-ALL) remain poorly characterized. Here, we have 63 
used 54 primary pediatric B-ALL samples to characterize the cellular-molecular mechanisms 64 
underlying the mitotic/chromosome defects predicated to be early pathogenic contributors in 65 
HyperD-ALL. We report that HyperD-ALL blasts are low proliferative and show a delay in early 66 
mitosis at prometaphase, associated to chromosome alignment defects at the metaphase plate 67 
leading to robust chromosome segregation defects and non-modal karyotypes. Mechanistically, 68 
biochemical, functional and mass-spectrometry assays revealed that condensin complex is 69 
impaired in HyperD-ALL cells, leading to chromosome hypocondensation, loss of centromere 70 
stiffness and mis-localization of the chromosome passenger complex proteins Aurora B Kinase 71 
(AURKB) and Survivin in early mitosis. HyperD-ALL cells show chromatid cohesion defects and 72 
impaired spindle assembly checkpoint (SAC) thus undergoing mitotic slippage due to defective 73 
AURKB and impaired SAC activity, downstream of condensin complex defects. Chromosome 74 
structure/condensation defects and hyperdiploidy were reproduced in healthy CD34+ 75 
stem/progenitor cells upon inhibition of AURKB and/or SAC. Collectively, hyperdiploid B-ALL is 76 
associated to defective condensin complex, AURKB and SAC. 77 
 78 
 79 




B-cell acute lymphoblastic leukemia (B-ALL) is characterized by the accumulation of abnormal 82 
immature B-cell precursors (BCP) in the bone marrow (BM), and is the most common pediatric 83 
cancer1. B-ALL is a heterogeneous disease with distinct biological-prognostic subgroups 84 
classified according to the stage at which BCPs are stalled in differentiation and 85 
cytogenetic/molecular markers1. Importantly, different biological subtypes of B-ALL have distinct 86 
causal mechanisms and show different clinical outcomes1-3.  87 
 88 
High hyperdiploid B-ALL (HyperD-ALL) is the most common subtype of childhood B-ALL and is 89 
characterized by the presence of 51-67 chromosomes in leukemic cells4-7. HyperD-ALL 90 
comprises 30% of pediatric B-ALL and usually has a favourable clinical outcome5,8,9. Of note, 91 
the distribution of chromosome gains is not random and preferentially show gains of 92 
chromosomes X, 4, 6, 10, 14, 17, 18 and 215,10. Hyperdiploidy is an initiating oncogenic event in 93 
B-ALL and secondary alterations necessary for clinical B-ALL accumulate subclonally and 94 
postnatally5,7,11,12.  Despite hyperdiploidy is the most common B-ALL in children, very little is 95 
known about its etiology and pathogenesis, and many questions about the biology of HyperD-ALL 96 
remain unanswered. Despite its favourable clinical outcome, a precise knowledge of the 97 
physiopathogenic mechanisms underlying HyperD-ALL is necessary because in absolute 98 
numbers, the morbidity/mortality associated to HyperD-ALL still represent a clinical challenge. 99 
 100 
HyperD-ALL is proposed to arise in a BCP in utero7. However, the causal molecular mechanisms 101 
of hyperdiploidy in BCPs remain elusive. In this sense, faithful chromosome segregation is 102 
essential for maintaining the genomic integrity of eukaryotic cells, and deficient chromosome 103 
segregation leads to aneuploidy and cancer13-15. Three main and non-mutually exclusive 104 
mechanisms, interconnected with mitosis16, underlie chromosome missegregation: (i) defects in 105 
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bipolar spindle formation, (ii) defects in chromosome structure and function, and (iii) defects in the 106 
spindle assembly checkpoint (SAC) which controls proper mitosis until chromosomes are properly 107 
attached to the spindle14-16. Indeed, SAC defects have been proposed to be an underlying 108 
pathogenic mechanism in rare cases of ETV6/RUNX1+ B-ALL with near-tetraploid karyotypes17. 109 
Therefore, abnormal mitotic control in BCP could be at the origin of hyperdiploidy in B-ALL.  110 
 111 
Here, we used a large cohort of primary pediatric B-ALL samples (n=54) to gain insights into the 112 
cellular and molecular mechanisms underlying mitotic/chromosome defects predicated to be at 113 
the origin of pediatric HyperD-ALL. Our data reveal that HyperD-ALL blasts show robust 114 
condensin complex defects and defective Aurora B kinase (AURKB) activity leading to abnormal 115 
mitotic progression and chromosome missegregation. Functional inhibition of AURKB and the 116 
SAC in normal hematopoietic stem/progenitor cells (HSPCs) reproduced hyperdiploid karyotypes 117 
with abnormal chromosome structure. We conclude that defects in condensin complex, AURKB, 118 


















Pediatric B-ALL leukemic samples and cell lines 135 
Diagnostic BM samples from B-ALL pediatric patients were obtained from collaborating hospitals. 136 
B-ALL diagnosis was based on FAB and WHO classifications1. Table S1 summarizes main 137 
clinico-biological data of the patients. Fetal tissue was collected from developing embryos aborted 138 
at 18 to 22 weeks of pregnancy, obtained from the MRC/Wellcome Trust Human Developmental 139 
Biology Resource upon informed consent and approval by our local ethics committee. The B-ALL 140 
cell lines SEM, REH and MHH-CALL-2 (DMSZ, Germany) were used for confirmatory studies. 141 
This study was approved by our Institutional Review Ethics Board (Barcelona Clínic-Hospital, 142 
HCB/2014/0687), and patient samples were accessed upon informed consent. 143 
 144 
In vivo expansion of B-ALL blasts  145 
All experimental procedures were approved by the Animal Care Committee of the Barcelona 146 
Biomedical Research Park (DAAM7393). Primary blasts (5x105) were expanded in vivo in 147 
sublethally irradiated 8-to-14-week-old non-obese diabetic/LtSz-scid IL-2Ry-/- mice (NSG) upon 148 
intra-BM transplantation18. PB was monitored by FACS for leukemia engraftment. Primografts 149 
were sacrificed when engraftment reached 10-15% in PB, typically representing >80% 150 
engraftment in BM. Blasts were isolated from BM and spleen by density-gradient centrifugation 151 
for downstream analysis. For FACS analysis of leukemic engraftment, PBMCs were stained with 152 
anti-human HLA-ABC-FITC, CD19-PE and CD45-APC antibodies (BD-Biosciences), and 153 
analysed using a FACS Canto-II cytometer.   154 
 155 
Indirect immunofluorescence  156 
B-ALL cells were spun on poly-L-lysine-coated coverslips (500g, 3min) before fixation. Cells were 157 
fixed and permeabilized with Triton X100-containing buffer (5min). Cells were blocked with 158 
permeabilization-buffer containing 1-3%BSA (1hour, 37°C), and incubated overnight at 4°C with 159 
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primary antibodies (Table S2). Cells were washed with permeabilization-buffer, and incubated 160 
(45min) with fluorophore-conjugated secondary antibodies (Jackson Labs). All antibodies were 161 
diluted in blocking-buffer. Slides were mounted with Vectashield-DAPI (VectorLab). Details of 162 
chromosome spreading for immunofluorescence are provided in Supplementary Methods. 163 
  164 
Confocal microscopy and image acquisition  165 
Microscope images were captured using a fully-equipped Zeiss LSM880 laser-scanning spectral 166 
confocal microscope equipped with an AxioObserver Z1 inverted microscope. DAPI, Alexa-488, 167 
Alexa Fluor-555 and Alexa Fluor-647 images were acquired sequentially using 405, 488, 561 and 168 
633 lasers, dichroic beam splitters, emission detection ranges of 415-480nm, 500-550nm, 571-169 
625nm and 643-680nm, respectively, and the confocal pinhole was set at 1 Airy units (AU). An 170 
acoustic optical beam splitter was used at the same emission detection ranges. Spectral 171 
detection was performed using two photomultipliers and one central GaAsP detector used for the 172 
acquisition of Alexa-647. Images were acquired in a 1024x300pixels format, zoom was set at 2, 173 
pixel size at 53x53nm and dwell time at 0.51µsec. Z-stacks were acquired at a 300nm step size 174 
to reconstruct the entire nuclei volume. Immunofluorescence signal quantification was performed 175 
using FIJI-ImageJ (NIH). Details of image quantifications are provided in Supplementary 176 
Methods.  177 
 178 
Details for in vitro culture/expansion of B-ALL cells and HSPCs, chromosome function and 179 
cytogenetic analysis, fluorescence quantification, western-blot and protein analysis, mass-180 
spectometry (MS) assays, cell cycle and phosphor-H3S10 quantification, RT-PCR, chromatin 181 
immunoprecipitation and RNA-sequencing are provided in Supplementary Methods and Tables 182 




Statistical analysis 185 
Statistical comparisons were performed using Graphpad Prism. Mean values and their standard 186 
error of the mean (s.e.m) were calculated for each variable. All data was analyzed according to 187 
the test indicated in the appropriate figure legends on the indicated number of experiments. Non-188 
HyperD were compared with HyperD B-ALLs. P<0.05 was considered statistically significant. 189 
 190 




HyperD-ALL cells are low proliferative and show a delay in early mitosis  193 
Aneuploid cells typically display a gene signature characterized by an up-regulation of genes 194 
involved in oxidative stress response, membrane functions and immune response regulation 195 
coupled to a down-regulation of genes involved in cell proliferation and nucleic acid metabolism19-196 
21. We first analysed the transcriptomic signature of HyperD-ALL blasts using a RNA-Seq dataset 197 
from HyperD-ALL patients (n=58) and non-HyperD B-ALL patients (n=30, non-aneuploid, Suppl 198 
methods)22. A Gene Ontology analysis of the 26,239 genes differentially expressed between 199 
primary HyperD-ALL and non-HyperD B-ALLs confirmed an aneuploidy-like gene expression 200 
signature characterized by the up-regulation of pathways associated with oxidative stress, protein 201 
turn-over, cell death, immune system activation and membrane functions (Fig 1a,b), and down-202 
regulation of pathways associated to nucleic acid metabolism and tRNA biology (Fig 1a,c). 203 
Consistent with this, we found that the aneuploid pediatric B-ALL cell line CALL-2 (doubled-up 204 
hypodiploid karyotype: 51XX,+X,+18,+der(18)t(15;18),+21,+21)23 exhibits a significantly lower 205 
proliferative rate than the non-HyperD-ALL cell lines SEM and REH (Fig 1d). Mechanistically, 206 
CALL-2 cells revealed a 5-fold increase in apoptosis coupled to an accumulation in G2/M (Fig 207 
1e,f), indicating cell division/mitotic defects in aneuploid B-ALL cells. 208 
 209 
To further characterize the mitotic progression of HyperD-ALL cells, we stained CALL-2, SEM 210 
and REH for DAPI, tubulin, pericentrin and the anti-centromere antibody (ACA) to unequivocally 211 
identify the different mitotic phases24 (Fig 1g). Consistent with the FACS data, 212 
immunofluorescence (IF) analysis revealed that CALL-2 cells accumulated in early mitosis, 213 
specifically at prometaphase/metaphase, with a concomitant delay in late mitosis (Fig 1h,i).  214 
 215 
Chromosome alignment defects in prometaphase underlie the mitotic delay of HyperD-ALL 216 
primary blasts 217 
9 
 
Cancer cell lines do not phenocopy faithfully the molecular complexity of the disease. 218 
Furthermore, despite CALL-2 is the only childhood HyperD-ALL cell line available, it actually 219 
represents a doubled-up hypodiploid B-ALL cell line23. We thus aimed to analyse the 220 
proliferation/mitotic defects in childhood HyperD-ALL primary blasts. Because leukemic primary 221 
cells fail to expand ex vivo25-27, we co-cultured B-ALL blasts with nestin+ fetal BM (FBM)-derived 222 
MSCs which support short-term proliferation of primary B-ALL blasts without compromising clonal 223 
composition28 (Fig 2a, Fig S1a,b). Similar to cell lines, non-HyperD-ALL primary cells grown on 224 
Nestin+ FBM-MSCs expanded 5-fold over a 6-day period while HyperD-ALL primary blasts failed 225 
to expand at all ex vivo (Fig 2b). FACS analysis using BM diagnostic samples also showed an 226 
increase in both apoptosis and frequency of G2/M cells in primary HyperD-ALL cells (Fig 2c,d). 227 
To further link proliferative impairment with mitotic defects, we analysed the mitotic progression in 228 
dividing B-ALL primary blasts expanded in vivo in NSG mice (Fig 2e, S2a). Xenografted blasts 229 
were processed and IF-stained for the DNA-Kinetochore-Spindle staining to unambiguously 230 
identify each mitotic phase (Fig 2f). Consistent with cell lines, HyperD-ALL primary blasts 231 
accumulated in early mitosis, at prometaphase/metaphase, with a concomitant delay in late 232 
mitosis (telophase and cytokinesis; Fig 2g, Fig S2b).  233 
 234 
Because chromosomes align at the metaphase plate in the prometaphase-to-metaphase 235 
transition, we then inspected dividing cells in early mitosis to distinguish between prometaphase 236 
(non-aligned chromosomes) and metaphase (aligned chromosomes) cells. We observed a robust 237 
decrease of HyperD-ALL blasts with aligned metaphase plates (Fig 2h), confirming chromosome 238 
alignment defects in early mitosis in HyperD-ALL cells. Chromosome alignment relies on the 239 
dynamics of chromosome biorentation to the spindle poles29. We thus analysed the dynamics of 240 
chromosome biorientation in primary B-ALL blasts by generating monopolar spindles and 241 
prometaphase arrest with monastrol (a spindle bipolarity inhibitor), followed by treatment with the 242 
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proteasome inhibitor MG132 which further arrests dividing cells in metaphase30 (Fig 2i). 243 
Strikingly, non-HyperD-ALL primary blasts properly aligned chromosomes at the metaphase plate 244 
in 90% of the metaphases (Fig 2j,k). However, HyperD-ALL samples showed a massive 245 
decrease in the number of cells with aligned chromosomes at the metaphase plate (45%) (Fig 246 
2j,k). Noteworthy, the defective chromosome biorientation in HyperD-ALL cells were confirmed in 247 
B-ALL cell lines (Fig S3a). Thus, the impaired proliferation of HyperD-ALL blasts may result from 248 
mitotic defects in prometaphase-metaphase due to aberrant chromosome alignment at the 249 
metaphase plate.   250 
 251 
Chromosome misalignment defects results in chromosome missegregation and non-252 
modal karyotypes in HyperD-ALL blasts 253 
Because defects in chromosome alignment often result in chromosome missegregation24, we 254 
next analysed the rates of chromosome segregation defects, mainly lagging chromosomes and 255 
anaphase bridges, in B-ALL blasts (Fig 3a). To overcome the accumulation of HyperD-ALL cells 256 
in early mitosis, B-ALL primary blasts were treated with the cytokinesis inhibitor Blebbistatin31. We 257 
found that HyperD-ALL primary blasts displayed a significant 4-fold higher number of late 258 
mitosis with chromosome segregation defects (Fig 3b). 259 
   260 
Since chromosome missegregation leads to aneuploidy, we analysed the modal karyotype 261 
distribution in 12 diagnostic B-ALL samples. We found a high chromosome stability in non-262 
HyperD B-ALL samples, with a modal chromosome number of 46 in >80% of the metaphases 263 
analysed (Fig 3c,d, Fig S4). However, HyperD-ALL blasts showed an increased karyotype 264 
instability defined by the presence of a major clone (40% of the cells) and minor clones with non-265 
modal chromosome distributions (Fig 3c, d, Fig S4). These results were confirmed by FISH 266 
analysis for chromosomes 12 and 21 (Fig 3e, f). Chromosome instability in HyperD-ALL cells was 267 
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further confirmed in B-ALL cell lines (Fig S3b,c). Collectively, chromosome alignment defects 268 
result in chromosome segregation defects and subsequent non-modal karyotypes in HyperD-ALL 269 
blasts. 270 
 271 
HyperD-ALL blasts show chromosome hypocondensation and loss of centromere 272 
stiffness due to condensin complex defects 273 
We next investigated the mechanisms leading to these mitotic/chromosome defects. IF analysis 274 
of the spindle using the DNA-Kinetochore-Spindle staining showed similarly low frequency of 275 
mitotic blasts with spindle abnormalities such as multipolar or disorganized spindles in non-276 
HyperD- and HyperD-ALL (Fig 4a). Moreover, defects in bipolar spindle formation frequently lead 277 
to cytokinesis defects and tetraploidization32. Since no (near)-tetraploid cells were observed in 278 
any HyperD-ALL patient (Fig 3c,d, Fig S4), we ruled out defects in spindle formation in HyperD-279 
ALL blasts. 280 
 281 
We next assessed whether chromosome structure and function underlies the mitotic defects 282 
observed in HyperD-ALL. We first examined the chromosome morphology of Carnoy-fixed 283 
pediatric B-ALL blasts (Table S1). While non-HyperD-ALL metaphases mostly showed normal 284 
rod-shaped chromosomes, 60% of HyperD-ALL metaphases displayed curly-285 
shaped/hypocondensed chromosomes with irregular borders (Fig 4b, S5a). Importantly, 286 
intrapatient comparison of diploid normal hematopoietic cells versus hyperD blasts confirmed that 287 
chromosome hypocondensation specifically occurs in HyperD-ALL cells (10% vs 70%, Fig S5b). 288 
Chromosome hypocondensation defects were further confirmed in B-ALL cell lines (Fig S5c). We 289 
next scored formaldehyde-fixed B-ALL samples for chromosome structure/condensation, and 290 
found significantly more metaphases containing hypocondensed and unstructured fuzzier and 291 
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wider chromosomes in HyperD-ALL than in non-HyperD-ALL blasts (80% vs 20%,p<0.001, Fig 292 
4c,d, S5d), excluding an impact of the fixative on chromosome structure/condensation defects.  293 
 294 
Condensin complexes are major components of the chromosome scaffold that regulate 295 
chromosome compaction and higher-order chromatin organization during mitosis33-36. The 296 
chromosome structure/condensation defects observed in HyperD-ALLs, prompted us to analyse 297 
in chromosome spreads from primary B-ALL samples the binding pattern of SMC2, a major 298 
component of condensin complexes. Non-HyperD-ALL blasts showed a normal beaded pattern 299 
for SMC2, spreading along the chromatids with a centromere enrichment (Fig 4e). In contrast, 300 
SMC2 was hardly detectable in neither chromatids nor centromeres, and showed an abnormal 301 
staining pattern in HyperD-ALL blasts (Fig 4e). Indeed, 3D image quantification of SMC2 staining 302 
revealed a significantly lower volume of SMC2 in chromosomes from HyperD-ALL blasts (Fig 4f, 303 
Fig S5e).  304 
 305 
To further characterize the defects in condensin complexes in HyperD-ALL samples, we analysed 306 
by WB in PDX-expanded B-ALL cells, the distinct protein members specific for each of the two 307 
human condensin complexes (complex I and II), which play a differential contribution to mitotic 308 
chromosome organization/segregation (Fig 4g). Protein analysis confirmed the lower levels of 309 
SMC2 in HyperD-ALL blasts, and revealed that both condensin complexes (CAPD2 and CAPD3) 310 
were similarly affected (Fig 4h,i). Strikingly, however, no differences were observed at the RNA 311 
level for any of the condensin complex members between HyperD-ALL and non-HyperD-ALL 312 
samples (Fig S5f), suggesting that post-translational modifications (PTM) may underlie 313 




Compelling data strongly suggest that PTMs are essential for regulating condensin loading to 316 
chromosomes37,38. We thus performed MS analyses for both SMC2 acetylation and CAPD2 317 
phosphorylation levels after immunoprecipitation of the condensin complexes with anti-SMC2 318 
(Fig S5g), and found increased levels of both SMC2 acetylation and CAPD2 phosphorylation in 319 
HyperD-ALL samples (Fig 4j-l), suggesting that PTMs regulating condensin activation may 320 
represent a mechanism underlying condensin defects in HyperD-ALL blasts.   321 
 322 
Condensin complexes set the stiffness of the centromeric chromatin required for withstand the 323 
spindle pulling forces during metaphase29, and SMC2 depletion results in increased 324 
intercentromeric distances in metaphase chromosomes39,40. To analyse centromere stiffness in 325 
HyperD-ALL blasts, we measured the intercentromeric distances between sister-kinetochore 326 
pairs in metaphase-arrested blasts (Fig 4m). For this, B-ALL blasts were metaphase-arrested 327 
with chromosomes under tension (non-relaxed length) or without tension (rest length) from the 328 
spindle, by using either the proteasome inhibitor MG132 or the microtubule depolymeriser 329 
colcemid, respectively. HyperD-ALL blasts consistently displayed a significant longer 330 
intercentromeric distance than non-HyperD-ALL blasts (Fig 4n,o). Collectively, PTMs of 331 
condensin members may induce a defective condensin complex which leads to high-order 332 
chromosome organization defects and impaired centromere stiffness/stretching at metaphase in 333 
HyperD-ALL blasts. 334 
 335 
Kinetochores are normal in HyperD-ALL blasts 336 
The kinetochore binds microtubules at centromeres and regulates chromosome segregation41. 337 
CENP-A (centromere-specific histone H3) and NDC80/NUF-2 are key centromere chromatin 338 
markers of the inner and outer kinetochore plate, respectively, which control kinetochore’s 339 
assembly. CENP-A overlaps with the condensin complex and it is flanked by the heterochromatin 340 
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histone marks H3K9me3 and H3K27me342-47. We thus prompted to study whether the condensin 341 
defects observed in HyperD-ALL blasts are associated to centromeric chromatin defects and 342 
destabilization of the kinetochore. ChIP-qPCR assays showed no differences of CENP-A, 343 
H3K9me3 or H3K27me3 levels at centromeres of HyperD-ALL blasts as compared to non-344 
HyperD-ALL blasts (Fig S6a). Moreover, quantitative confocal microscopy analysis revealed very 345 
similar levels of NUF-2 between HyperD-ALL and non-HyperD-ALL blasts (Fig S6b,c), indicating 346 
that despite impaired centromere stiffness, the centrochromatin is not epigenetically impaired and 347 
the kinetochore forms normally in HyperD-ALL blasts.  348 
 349 
The chromosome passenger complex (CPC) proteins AURKB and Survivin are mis-350 
localized from the inner-centromere in early mitotic HyperD-ALL blasts 351 
We next aimed to analyse the cellular mechanisms by which the impaired condensin complex 352 
leads to mitotic/chromosome defects in HyperD-ALL blasts. We first analysed the CPC, a protein 353 
complex composed by AURKB and the accessory subunits Survivin, Borealin and INCENP. The 354 
CPC regulates the SAC to ensure proper kinetochore-microtubule attachment, and was shown 355 
mis-localized from the inner-centromere in cells with defective condensin complex34,48,49. 356 
Prometaphase-arrested nonHyperD-ALL primary blasts revealed a normal chromosomal 357 
distribution of both AURKB and Survivin mainly concentrated in the inner-centromere (Fig 5a,b). 358 
However, HyperD-ALL blasts showed an aberrant chromosomal distribution of both AURKB and 359 
Survivin, diffusely distributed throughout the chromosome arms rather than concentrated in the 360 
inner-centromere (Fig 5a,b). Quantification of both AURKB and Survivin at the inner-centromeres 361 
confirmed a significant decrease of both CPC proteins in centromeres of HyperD-ALL blasts (Fig 362 
5c,d, S7a,b). To further characterize the localization of AURKB and Survivin, we analysed the 363 
frequency of chromosomes showing either centromeric or scattered localization (Fig 5e), and 364 
confirmed that HyperD-ALL blasts preferentially showed scattered localization throughout the 365 
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chromosome arms (Fig 5f,g). These results were reproduced using B-ALL cell lines (Fig S7c,d). 366 
Of note, the overall chromosome-wide expression levels of both AURKB and phospho-histone H3 367 
at Serine 10 (H3S10p), the major readout of AURKB activity, were significantly reduced in 368 
HyperD-ALL blasts (Fig 5h,i). Finally, we generated condensin complex I-defective non-HyperD-369 
ALL cell lines by knocking down CAPD2, and confirmed the mis-localization of AURKB from the 370 
inner-centromere (Fig S7e,f). Taken together, mis-localization of the CPC proteins AURKB and 371 
Survivin in early mitosis represents a major mechanism linking defective condensin complex and 372 
chromosome alignment/segregation defects in HyperD-ALL blasts. 373 
 374 
Defective AURKB is associated with loss of chromatid cohesion and SAC impairment in 375 
HyperD-ALL blasts 376 
The confined localization of AURKB at the inner-centromere is essential for chromatid cohesion 377 
and proper SAC activity30,50,51. Indeed, analysis of chromosome spreads revealed that 75% of the 378 
metaphases from HyperD-ALL blasts displayed “rail-road chromosomes”, a common phenotype 379 
reflecting premature chromatid separation (PCS) due to reduced chromatid cohesion at 380 
centromeres (Fig 5j, S8a). These results were reproduced using B-ALL cell lines (Fig S8b). 381 
 382 
AURKB controls chromosome biorientation/alignment at the metaphase plate through 383 
phosphorylation of different SAC proteins30,50,52,53. We thus reasoned that AURKB defects may 384 
underlie the progression towards late mitosis of HyperD-ALL blasts with mis-aligned 385 
chromosomes by preventing SAC activation. To test this, we co-cultured B-ALL primografts on 386 
Nestin+ FBM-MSC in the presence of nocodazol, which generates persistently unattached 387 
kinetochores leading to SAC activation and mitotic accumulation (Fig 5k), and found that 388 
nocodazol-treated HyperD-ALL blasts did not accumulate in mitosis as efficiently as non-HyperD-389 
ALL blasts (Fig 5l,m). These results were reproduced in B-ALL cell lines (Fig S8c). Cell cycle 390 
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analysis further confirmed that HyperD-ALL blasts do not arrest in G2/M after nocodazol 391 
treatment but they accumulate in G0/G1 (Fig 5n,o), strongly suggesting mitotic slippage. 392 
Apoptosis was not different between HyperD-ALL and non-HyperD-ALL blasts (Fig S8d). 393 
Noteworthy, the metaphase-to-anaphase promoting regulator MAD2L2, whose loss leads to 394 
accelerated mitosis and mitotic aberrations54 was found downregulated in HyperD-ALL blasts (Fig 395 
5p). Collectively, HyperD-ALL cells show chromatid cohesion defects and undergo mitotic 396 
slippage most likely due to defective AURKB and impaired SAC activity, downstream of 397 
condensin complex defects. 398 
 399 
Inhibition of AURKB and SAC in CD34+ HSPCs reproduces chromosome structure defects 400 
and hyperdiploid karyotypes 401 
We next prompted to functionally model whether defective AURKB and impaired SAC activity 402 
could reproduce the phenotype observed in HyperD-ALL primary blasts. Because hyperD-ALL 403 
was shown to have a prenatal origin and pre-leukemic hyperdiploid precursors are found at 404 
birth55,56, we exposed fetal BM-derived CD34+ HSPCs to the AURKB inhibitor ZM447439 and/or 405 
to the SAC inhibitor Reversine for 48h, and then processed cells for cytogenetics analysis (Fig 406 
6a,b). Both AURKB and SAC inhibition in CD34+ HSPCs reproduced chromosome structure 407 
defects observed in HyperD-ALL (Fig 6b, S9a). They both drastically increased (compared to 408 
controls) the frequency of CD34+ HSPCs with micronuclei, a bona fide marker of chromosome 409 
instability (Fig 6c), hypocondensed chromosomes (Fig 6d), and metaphases with PCS reflecting 410 
loss of chromatid cohesion (Fig 6e).Such chromosome structure defects were maintained and/or 411 
slighted potentiated when both AURKB and SAC were simultaneously inhibited (Fig 6b-e). Of 412 
note, despite we could not reliably assess the karyotypes of reversine-treated CD34+ HSPCs due 413 
to massive chromosome damage, AURKB inhibition resulted in 30% of the CD34+ HSPCs 414 
displaying hyperdiploid karyotypes (Fig 6f, S9b,c). In addition, cell cycle analysis revealed 415 
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massive alterations in DNA ploidy, confirming genomic imbalances in CD34+ cells upon 416 
treatment with AURKB or SAC inhibitors (Fig 6g). The chromosome structure defects and 417 
hyperdiploid karyotypes reproduced in CD34+ cells reinforce defective AURKB and SAC as an 418 





This is the most comprehensive study to date on the cellular mechanisms underlying the mitotic 422 
and chromosome defects contributing to the pathophysiology of pediatric HyperD-ALL. Here, we 423 
have developed robust in vitro assays using nestin+ fetal BM-MSCs and in vivo PDX to 424 
successfully expand primary B-ALL leukemic samples. Such ex vivo and in vivo expansion of B-425 
ALL leukemic samples provided enough mitotic/dividing primary blasts for addressing many 426 
biological questions in a large cohort of 54 primary B-ALL samples, thus highlighting the clinical 427 
relevance of our work. The only available hyperD-ALL cell line CALL-2 was used throughout the 428 
study for confirmatory and gain-of-function studies, and consistently phenocopied the data 429 
generated using primary HyperD-ALL primary cells. This cell line originates from a doubled-up 430 
hypodiploid B-ALL23, suggesting that the same mitotic/chromosomal defects here reported may 431 
underlie the pathogenesis of hypo-diploid B-ALL patients. Future studies, however, should be 432 
done in HypoD-ALL patients who are rare but clinically dismal. 433 
 434 
We demonstrate that in contrast to nonHyperD-ALL, HyperD-ALL blasts show reduced 435 
proliferative rates coupled to a delay in early mitosis at prometaphase. Such a delay in early 436 
mitosis is associated to chromosome alignment defects at the metaphase plate which, in fact, 437 
lead to chromosome segregation defects and non-modal karyotypes. Despite karyotype 438 
heterogeneity, HyperD-ALL primary blasts show a major clone that most likely represents the 439 
fittest clone after cell adaptation to aneuploidy57. These data supports previous studies showing 440 
the presence of cytogenetically different subclones in HyperD-ALL58-61.  441 
 442 
Mechanistically, HyperD-ALL primary blasts and cell lines did not show abnormalities in bipolar 443 
spindle and kinetochore formation. However, they displayed important chromosome structure and 444 
function defects, a major mechanism regulating chromosome segregation which is essential for 445 
maintaining the genomic integrity of cells13-15. HyperD-ALL cells showed robust defects in several 446 
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members of the condensin complexes including SMC2 (levels reduced at chromosome scaffolds), 447 
CAPD2 and CAPD3. Biochemical, functional and MS assays revealed that PTMs of condensin 448 
complex proteins may represent a mechanism underlying defective condensin complexes in 449 
HyperD-ALL cells. Of note, no mutations were found in condensin complex- encoding genes in 450 
HyperD-ALL patients, ruling out genomic mutations as the cause of the defective condensin 451 
complex in HyperD-ALL patients. 452 
 453 
Consequently, high-order chromosome architecture defects are notorious, and include 454 
chromosome hypocondensation and loss of centromere rigidity revealed by increased 455 
intercentromeric distances. Consistently, a recent study has reported chromosome architecture 456 
defects and lower expression of CTCF in HyperD-ALL samples62. Furthermore, AURKB, the 457 
catalytic subunit of the CPC, and Survivin are mis-localized from the inner-centromere in early 458 
mitosis, further linking defective condensin with chromosome segregation defects in HyperD-ALL 459 
blasts. According to the essential localization of AURKB at the inner-centromere to protect 460 
chromatid cohesion and for proper SAC activity30,50,51, HyperD blasts show chromatid cohesion 461 
defects as observed by PCS and impaired SAC, leading to mitotic slippage. Impaired SAC activity 462 
explains why HyperD-ALL blasts proceed to late mitosis with misaligned chromosomes at the 463 
metaphase plate, thus leading to chromosome segregation defects. Importantly, chromosome 464 
hypocondensation and hyperdiploidy were functionally reproduced in CD34+ HSPC upon 465 
inhibition of AURKB and/or SAC, reinforcing defective condensin complex, AURKB and SAC as 466 
underlying cellular and molecular mechanisms in HyperD-ALL (Figure 7). Although they are likely 467 
instrumental in the pathophysiology of the HyperD-ALL, whether these findings are causal or 468 




This is the first cellular and molecular in-depth characterization of the mitotic and chromosomal 471 
defects of HyperD-ALL using a cohort of 54 B-ALL primary samples. It represents a highly 472 
relevant study because B-ALL is the most common pediatric cancer. Studies in monozygotic 473 
twins with concordant HyperD-ALL and retrospective analysis of HyperD clones in cord blood 474 
indicated that HyperD clones arise prenatally7, and that hyperdiploidy is an initiating oncogenic 475 
event generating a preleukemic clone which then requires secondary mutations to trigger a full-476 
blown leukemia63. Therefore, a better mechanistic understanding of how hyperdiploidy occurs 477 
and how secondary alterations are acquired becomes crucial not only to propose novel 478 
therapeutic targets but also to prevent the progression/relapse of HyperD-ALL. These defects in 479 
condensin complex-AURBK-SAC axis open up new avenues for modelling HyperD-ALL by 480 
genetically engineering of HSPCs, which will be crucial to further address the causal contribution 481 
of these defects to the origin of HyperD in B-ALL.  482 
 483 
From a diagnostic-clinical standpoint, the high-order chromatin/chromosome structural defects 484 
observed in HyperD-ALL explains very well the difficulties that clinical cytogeneticists have 485 
historically encountered to obtain metaphases of standard quality from these patients, thus 486 
challenging the cytogenetic diagnostic3. In addition, despite the favourable clinical outcome of 487 
HyperD-ALL, unravelling the physiopathogenic mechanisms underlying HyperD-ALL is necessary 488 
because in absolute numbers, the morbidity/mortality associated to HyperD-ALL still represent a 489 
clinical challenge. In sum, this study seeds light on the mechanisms underlying the mitotic and 490 
chromosome defects involved in the pathogenesis of HyperD-ALL and offers molecular targets 491 
(Condensin complex members, CPC members -AURKB- or the SAC) for potential 492 
pharmacological intervention in the most frequent molecular subtype of pediatric acute leukemia. 493 
  494 
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FIGURE LEGENDS: 699 
 700 
FIGURE 1: HyperD-ALL cells are low proliferative and show a delay in early mitosis. (a) 701 
Heat map of the top 50 genes more differentially expressed between HyperD (n=58) and non-702 
HyperD (n=30) B-ALL samples. (b-c) Top 20 statistically significant up-regulated (b) or down-703 
regulated (c) biological pathways identified using GSEA for the genes differentially expressed in 704 
HyperD versus nonHyperD-ALL patients. Coloured bars represent normalized enrichment scores 705 
(NES). p-values are shown. (d) 16-day proliferation curves for the indicated cell lines, n=3 706 
independent experiments. (e) SubG0/SubG1 apoptotic levels identified by FACS for the indicated 707 
cell lines, n=3 independent experiments. (f) Cell cycle analysis for the indicated cell lines. Left, 708 
representative cell cycle FACS analysis. Right, frequency of cells in G2/M analysed, n=3 709 
independent experiments. (g) Representative DNA-Kinetochore-spindle IF staining (DNA, ACA, 710 
tubulin, and pericentrin) identifying the different mitotic phases in B-ALL cell lines. The SAC 711 
identifies the transition from early to late mitosis. P: Prophase, PM: Prometaphase, M: 712 
Metaphase, A: Anaphase, T: Telophase, CK: Cytokinesis. Scale bar=10 µm. (h,i) Mitosis 713 
progression in B-ALL cell lines. Progression from early to late mitosis (h), and frequency of cells 714 
at the indicated mitotic phases (i), n=4 independent experiments. Graphs represent the mean, 715 
and error bars represent the s.e.m. *p<0.05, **p<0.01 (Two-way ANOVA).  716 
 717 
FIGURE 2: HyperD-ALL primary blasts show a delay in early mitosis associated with 718 
chromosome alignment defects in prometaphase. (a) Schematic depicting the experimental 719 
design for ex vivo growth of primary B-ALL blasts onto nestin+ hBM-MSCs. (b) Left, 720 
representative images of primary non-HyperD and HyperD-B-ALL ex vivo cultures on nestin+ 721 
hBM-MSCs at the indicated time-points. Right, absolute counts of B-ALL primary blasts at the 722 
indicated time-points, n=2. (c,d) Frequency of apoptotic (SubG0/SubG1) (c) and G2/M (d) non-723 
HyperD and HyperD-ALL primary cells from BM samples, n=3 patients of each. (e) Schematic 724 
27 
 
depicting the PDX model used to expand primary B-ALL blasts in vivo. (f) Representative DNA 725 
(blue)-Kinetochore (purple)-spindle (red-green) IF staining identifying the different mitotic phases 726 
in PDX-expanded B-ALLs. The SAC identifies the transition from early to late mitosis. (g) Mitosis 727 
progression of PDX-expanded B-ALL primary cells. Left, progression from early to late mitosis. 728 
Right, frequency of cells at the indicated mitotic phases, n=3 non-HyperD and n=5 HyperD PDX-729 
expanded B-ALLs. (h) Left, representative images of mitotic cells with non-aligned and aligned 730 
chromosomes at the metaphase plate. Right, frequency of PDX-expanded B-ALL primary blasts 731 
showing chromosome alignment at prometaphase/metaphase, n=4 non-HyperD and n=4 HyperD 732 
PDX-expanded B-ALLs. (i) Schematic depicting the chromosome biorientation assay. (j) 733 
Representative images of the DNA-Kinetochore-spindle staining in monastrol/MG132-treated 734 
cells with 0 (left), 1 (middle) and >2 (right) misaligned chromosomes. (k) Quantification of 735 
metaphase cells showing misaligned chromosomes, n=3 non-HyperD and n=3 HyperD PDX-736 
expanded B-ALLs. Graphs represent the mean, and error bars represent the s.e.m. *p<0.05, 737 
**p<0.01; ***p<0.0001 (Two-way ANOVA). Scale bars=10 µm.  738 
 739 
FIGURE 3: Chromosome segregation defects and non-modal karyotypes in HyperD-ALL 740 
blasts. (a) Representative DNA (blue)-Kinetochore (green)-spindle (red) IF staining identifying 741 
lagging and bridge chromosomes. Yellow arrowheads depict the indicated chromosome 742 
segregation defect. (b) Frequency of blebbistatin-treated mitotic PDX-expanded primary blasts 743 
with lagging and bridge chromosomes, n=151 mitosis from 3 non-HyperD and 96 mitosis from 3 744 
HyperD-ALLs. (c) Comparison of modal karyotypes from 50 metaphases from primary HyperD 745 
(n=6) and non-HyperD (n=6) B-ALL samples. (d) Frequency of cells showing modal karyotype. 746 
(e,f) FISH analysis using DNA probes for chromosomes 12 (green) and 21 (red) of 200 747 
interphase nuclei from n=3 non-HyperD and 4 HyperD-ALL primary samples. (e) Frequency of 748 
cells representing the modal clone versus minor clones. (f) Representative FISH analysis for a 749 
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primary non-HyperD and a HyperD-ALL. Graphs represent the mean and error bars represent the 750 
s.e.m. *p<0.05, **p<0.01; ***p<0.0001 (Two-way ANOVA). Scale bars=10 µm. 751 
 752 
FIGURE 4: HyperD-ALL blasts show chromosome hypocondensation, loss of centromere 753 
stiffness, and defects in the condensin complex. (a) Analysis of spindle abnormalities in B-754 
ALL primary blasts. Left, representative DNA-Kinetochore-spindle IF staining of mitotic cells with 755 
bipolar, multipolar and disorganized spindles. Right, frequency of mitotic cells displaying spindle 756 
defects, n=3 non-HyperD-ALLs (n=251 mitosis) and n=3 HyperD-ALLs (n=251 mitosis) PDX-757 
expanded samples. (b) Frequency of metaphases with hypocondensed chromosomes in primary 758 
B-ALL blasts, n=200 metaphases from 4 Non-HyperD and n=250 metaphases from 5 HyperD-759 
ALLs primary samples. Left, representative images of normal and hypocondensed metaphase 760 
chromosomes. Insets represent 3x magnifications. (c) Chromosome structure of formaldehyde-761 
crosslinked PDX-expanded B-ALL samples. Left, representative images of metaphase cells with 762 
hypocondensed chromosomes. Anti-ACA staining is shown in green. Right, frequency of 763 
formaldehyde-crosslinked metaphases showing hypocondensed or hypocondensed with 764 
unstructured chromosomes in B-ALL primary samples, n=60 metaphases from 3 non-HyperD and 765 
n=57 metaphases from 3 HyperD-ALLs. (d) Chromosome arm width using PDX-expanded B-ALL 766 
samples from c, n=191 chromosomes from 3 non-HyperD and n=143 chromosomes from 3 767 
HyperD-ALLs. (e) Representative IF images of metaphase PDX-expanded B-ALL blasts stained 768 
with DAPI, anti-SMC2 and anti-ACA. (f) Quantification of the SMC2 total volume in metaphase 769 
chromosomes from e, n=30 metaphases from 3 non-HyperD and 3 HyperD-ALLs. (g) Schematic 770 
cartoon of the two human condensin complexes. (h) WB analysis of the indicated condensin 771 
members in whole-cell lysates from PDX-expanded B-ALL samples. (i) Quantification of WB 772 
bands from h normalized to actin. (j) Representative HPLC-ESI-MS chromatograms of the 773 
indicated peptides for HyperD and non-HyperD PDX-expanded B-ALLs. (k) Acetylation levels of 774 
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SMC2 peptide SQAASILTK (m/z=480.8). (l) Phosphorylation levels of CAPD2 peptide 775 
GPAASTQEK (m/z=524.7). Results depict the average of the peak areas from independent MS 776 
experiments from 2 non-HyperD and 2 HyperD-ALL PDX-expanded blasts. (m) Representative 777 
line-scan measurements of individual centromeres in the indicated B-ALL primary samples. DAPI 778 
and ACA are depicted as a blue and red lines, respectively. Yellow arrowheads point to the 779 
analysed chromosome. (n) Intercentromeric distance from MG132-treated PDX-expanded B-ALL 780 
blasts, n=155 centromeres from 3 non-HyperD and n=119 centromeres from 3 HyperD-ALLs. (o) 781 
Intercentromeric distance from colcemid-treated PDX-expanded B-ALL blasts, n=130 782 
centromeres from 3 non-HyperD and n=111 centromeres from 3 HyperD-ALLs. Graphs represent 783 
the mean and error bars represent the s.em. *p<0.05, **p<0.01; ***p<0.001; **** p<0.0001. Two-784 
way ANOVA (b,c) or t-Student (a,d,f,h,i). Scale bars=10 µm. 785 
 786 
FIGURE 5: Mis-localized AURKB and Survivin from the inner centromere and loss of 787 
chromatid cohesion and SAC impairment in HyperD-ALL blasts. (a,b) Representative IF 788 
staining for CENP-A and AURKB (a) or Survivin (b) in PDX-expanded B-ALL blasts. (c,d) 789 
Quantification of the AURKB (c) and Survivin (d) fluorescence signal at the inner centromere, 790 
n=30 metaphases from 3 non-HyperD and n=30 metaphases from 3 HyperD-ALL. (e) 791 
Representative IF showing either centromeric and scattered localization of AURKB, Survivin and 792 
CENP-A. (f,g) Frequency of PDX-expanded non-HyperD (n=3) and HyperD-ALL (n=3) blasts 793 
showing centromeric versus scattered localization of AURKB (n=797 chromosomes from non-794 
HyperD and n=676 chromosomes from HyperD) (f), and Survivin (n=964 chromosomes from non-795 
HyperD and n=814 chromosomes from HyperD) (g). (h) Quantification of total AURKB 796 
fluorescence signal from samples in c. AURKB levels are expressed relative to non-HyperD 797 
blasts, which are arbitrarily set to 100. (i) Left, representative FACS staining of H3S10P. Right, 798 
MFI of H3S10P in 3 non-HyperD and 3 HyperD-ALL samples. (j) Left, representative images of 799 
30 
 
normal or rail-road shaped chromosomes. Right, frequency of metaphases showing the indicated 800 
number of chromosomes with PCS; n=200 metaphases from 4 non-HyperD, n=250 metaphases 801 
from 5 HyperD-ALLs samples. (k) Schematic depicting the workflow for functional analysis of the 802 
SAC. (l) Representative FACS of mitotic PDX-expanded B-ALL blasts (H3S10P+CD19+ cells, 803 
green) in the presence or absence of nocodazole. (m) Fold-change of mitotic (H3S10P+) blasts in 804 
nocodazol-treated (relative to DMSO-treated) non-HyperD (n=3) and HyperD-ALL (n=3) primary 805 
blasts. (n) Representative FACS cell cycle distribution of nocodazol- versus DMSO-treated PDX-806 
expanded B-ALL blasts. (o) Quantification of the cell cycle phases in nocodazol- versus DMSO-807 
treated PDX-expanded B-ALL blasts, n=3 non-HyperD and n=3 HyperD-ALL. (p) qRT-PCR 808 
analysis of SAC proteins in B-ALL primary samples, n=9 non-HyperD and n=11 HyperD. Graphs 809 
represent the mean and error bars represent the s.e.m. *p<0.05, **p<0.01; ***p<0.001; **** 810 
p<0.0001 (two-way ANOVA or t-Student). Scale bars=10 µm.  811 
 812 
FIGURE 6: Inhibition of AURKB and SAC in CD34+ HSPCs reproduces chromosome 813 
structure defects and hyperdiploid karyotypes. (a) Schematic depicting the workflow for 814 
AURKB and SAC inhibition in CD34+ HSPCs. (b) Representative images of metaphase 815 
chromosomes treated as indicated. (c-f) Frequency of metaphases with micronuclei (n=500 cells 816 
per experiment) (c), hypocondensed chromosomes (d), PCS (e) and hyperdiploidy karyotype (f). 817 
(g) Representative FACS analysis showing PI staining profiles in CD34+ HSPCs treated as 818 
indicated. n=150 metaphases were analysed per treatment from 3 independent experiments. 819 
*p<0.05, **p<0.01 (One-tail t-Student).  820 
 821 
FIGURE 7: Proposed model of the cellular mechanisms underlying the mitotic and chromosome 822 
defects contributing to the pathophysiology of pediatric HyperD-ALL.  823 







